Short summary: A new study in Diabetes Care found that state insulin out-of-pocket cost caps may reduce costs for some commercially insured adults. But many adults who use insulin remain outside these state protections because of plan type, state rules, and gaps in where the laws apply.
What happened
Researchers reviewed state insulin out-of-pocket cap policies enacted through 2026 and estimated how many adults with diabetes using insulin may be reached by these laws. The study focused on commercially insured adults aged 18 to 64 in the United States.
The key finding is practical: state-level insulin caps can help, but they do not reach everyone who pays for insulin. By 2026, the researchers found that 29 states and Washington, DC had enacted insulin out-of-pocket cap laws. They estimated that these laws covered about 0.99 million adults with diabetes using insulin who were enrolled in state-regulated commercial insurance plans.
Why this matters
Insulin affordability is not a small policy detail. For people who need insulin, high costs can affect whether doses are taken as prescribed, whether refills are delayed, and whether diabetes care becomes financially stressful.
The study helps explain why one person may see lower out-of-pocket insulin costs while another person, sometimes in the same state, may not. The difference can depend on whether the insurance plan is regulated by the state, whether the state has an insulin cap, and how the plan applies pharmacy benefits.
What the study found
The authors estimated that insulin cost caps reached many people, but left large gaps:
- About 0.99 million adults with diabetes using insulin were estimated to be covered by state out-of-pocket cap laws through state-regulated commercial plans.
- About 0.67 million adults with diabetes using insulin were in state-regulated commercial plans but lived in states without insulin out-of-pocket cap legislation.
- About 2.2 million adults with diabetes using insulin were in federally regulated commercial plans, which fall outside state jurisdiction.
That means state laws may reduce costs for some insulin users, but they cannot fully solve insulin affordability for everyone.
Who may not be protected
The study points to an important distinction: not all commercial insurance is regulated by the state. Many employer plans are federally regulated, especially self-funded employer plans. State insulin cap laws generally do not apply to those plans.
The study also did not cover every insurance situation. It focused on commercially insured adults aged 18 to 64. It did not directly estimate protections for people with Medicare, Medicaid, no insurance, or coverage outside the study definition.
Practical takeaway
If you use insulin, the most useful next step is to understand your own coverage. You can ask your insurer, employer benefits office, pharmacist, or diabetes clinic whether your plan is state-regulated or federally regulated, whether your state has an insulin out-of-pocket cap, and whether the cap applies to your specific insulin and pharmacy benefit.
Do not ration insulin or change insulin doses because of cost without urgent help from your diabetes team. If insulin is unaffordable, ask about patient assistance programs, lower-cost insulin options, formulary alternatives, emergency supply rules, community clinics, and state or local support programs.
Evidence and source summary
The source is a peer-reviewed Diabetes Care article titled “State Insulin Out-of-Pocket Cap Policies and Estimated Eligible Populations in the United States, 2019-2026.” The article was published online on June 30, 2026.
The study used public data on diabetes prevalence and health insurance coverage to estimate the reach of state insulin out-of-pocket cap laws. It evaluated policy reach, not clinical outcomes such as A1C, complications, hospital visits, or medication adherence.
- Primary source: PubMed record
- Journal DOI: Diabetes Care DOI page
Important caveats
- This is a U.S. policy study. It does not apply directly to insulin prices or insurance systems in other countries.
- The estimates depend on insurance categories and state policies through 2026. Laws, formularies, and plan designs can change.
- The study does not prove that cost caps improved blood glucose, reduced complications, or changed insulin use. It estimates who may be reached by the policies.
- Personal insulin costs can still vary by plan, pharmacy benefit, deductible, insulin type, and state.
Suggested categories and tags
Categories: News, Type 1 diabetes, Type 2 diabetes, Diabetes Medication.
Tags: insulin cost caps, insulin affordability, insulin, diabetes medication, health policy, Diabetes Care.